Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study

  • Shuangshuang Song
  • Ye Cheng
  • Jie Ma
  • Leiming Wang
  • Chengyan Dong
  • Yukui Wei
  • Geng Xu
  • Yang An
  • Zhigang Qi
  • Qingtang LinEmail author
  • Jie LuEmail author
Open Access
Original Article
Part of the following topical collections:
  1. Oncology – Brain



Glioma treatment planning requires precise tumor delineation, which is typically performed with contrast-enhanced (CE) MRI. However, CE MRI fails to reflect the entire extent of glioma. O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) PET may detect tumor volumes missed by CE MRI. We investigated the clinical value of simultaneous FET-PET and CE MRI in delineating tumor extent before treatment planning. Guided stereotactic biopsy was used to validate the findings.


Conventional MRI and 18F-FET PET were performed simultaneously on a hybrid PET/MR in 33 patients with histopathologically confirmed glioma. Tumor volumes were quantified using a tumor-to-brain ratio ≥ 1.6 (VPET) and a visual threshold (VCE). We visually assessed abnormal areas on FLAIR images and calculated Dice’s coefficient (DSC), overlap volume (OV), discrepancy-PET, and discrepancy-CE. Additionally, several stereotactic biopsy samples were taken from “matched” or “mismatched” FET-PET and CE MRI regions.


Among 31 patients (93.94%), FET-PET delineated significantly larger tumor volumes than CE MRI (77.84 ± 51.74 cm3 vs. 34.59 ± 27.07 cm3, P < 0.05). Of the 21 biopsy samples obtained from regions with increased FET uptake, all were histopathologically confirmed as glioma tissue or tumor infiltration, whereas only 13 showed enhancement on CE MRI. Among all patients, the spatial similarity between VPET and VCE was low (average DSC 0.56 ± 0.22), while the overlap was high (average OV 0.95 ± 0.08). The discrepancy-CE and discrepancy-PET were lower than 10% in 28 and 0 patients, respectively. Eleven patients showed VPET partially beyond abnormal signal areas on FLAIR images.


The metabolically active biodistribution of gliomas delineated with FET-PET significantly exceeds tumor volume on CE MRI, and histopathology confirms these findings. Our preliminary results indicate that combining the anatomic and molecular information obtained from conventional MRI and FET-PET would reveal a more accurate glioma extent, which is critical for individualized treatment planning.


FET Contrast-enhanced MRI Glioma Tumor volume Stereotactic biopsy Hybrid PET/MR 


For patients with malignant glioma, continuous efforts were made to improve the overall survival and prognosis [1, 2]. Recently, several promising treatment methods, such as the addition of lomustine or tumor-treating fields into standard temozolomide maintenance therapy, shed light on the treatment of malignant glioma, which effectively prolonged 30–55% of median overall survival compared with temozolomide standard therapy [3, 4]. These novel treatments indicated the advancement of the chemotherapies on malignant gliomas and may become new standards of patient care.

As the widely accepted standard treatment for malignant glioma, surgical resection mainly relies on noninvasive imaging to delineate tumor extent. The extent of surgical resection and the residual tumor volumes are pivotal factors that affect the recurrence rate and the prognosis of glioma patients [5, 6]. In general, multimodality imaging plays an essential role in the diagnosis and neurosurgical planning for gliomas [7, 8, 9, 10]. Among these approaches, contrast-enhanced (CE) magnetic resonance imaging (MRI) is the mainstay to delineate tumor boundaries and guide further therapies [11]. However, CE MRI, when used alone or in combination with T2 and fluid-attenuated inversion recovery (FLAIR) imaging, may not reliably reflect the entire tumor burden [12, 13]. Consequently, a technique that could delineate the tumor extent more precisely is needed for therapeutic target planning.

The increasing application of positron emission tomography (PET) has improved the diagnosis and clinical management of gliomas [14, 15, 16, 17, 18]. The European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the working group for Response Assessment in Neurooncology with PET (PET-RANO) have published joint practice guidelines for the use of amino acid PET tracers in glioma imaging and recommended that molecular imaging should be used as a supplement to MRI in the clinical management of gliomas [17]. Compared with 2-deoxy-2-[18F]fluoro-d-glucose (18F-FDG), amino acid PET tracers, such as 11C-methyl-methionine (11C-MET), O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET), and 3,4-dihydroxy-6-[18F]fluoro-l-phenylalanine (18F-DOPA), exhibit lower uptake in normal brain and inflammatory tissues than in gliomas and thus present clearer tumor borders with a higher tumor-to-background contrast [19, 20]. The half-life of 18F (110 min) is longer than that of 11C (20 min), making 18F-FET more suitable for routine clinical applications in neurooncology [21]. Furthermore, FET has high in vivo stability and is efficiently synthesized by nucleophilic reactions.

Compared with CE MRI, amino acid PET imaging, when used with tracers such as 11C-MET [19, 22] and 18F-FET [23], often reveals a larger tumor spatial distribution in GBM patients. Among these previous studies, simultaneous PET and MRI acquisition was used with a hybrid PET/MR only in Lohnmann’s study (35 of 50 patients). Other studies used PET and MRI scans obtained on separate occasions, which would therefore not reflect the spatial distribution characteristics of glioma in the same pathological state. In addition, these previous studies were based only on imaging feature assessment without any pathological validation.

In this study, we evaluated the clinical value of hybrid FET-PET/MR in delineating tumor extent and guiding stereotactic biopsies in patients with glioma. The spatial similarity, overlap, discrepancy, and spatial correlation of tumor volumes were analyzed and compared between FET-PET and CE MRI. To better comprehend the imaging findings, several stereotactic biopsy samples were taken from regions showing either substantial overlap or mismatch between FET-PET and CE MR to further assess and validate the clinical potential of hybrid scans in guiding biopsy and surgery.

Materials and methods

Patients data

From February 2019 to July 2019, a total of 33 patients with newly diagnosed or recurrent supratentorial gliomas who underwent hybrid 18F-FET-PET/MR imaging prior to biopsy or gross resection were retrospectively recruited into this study (Table 1). The diagnosis of glioma was supported by pathological histology according to the 2016 WHO classification system. The Ethics Committee and Institutional Review Board of Xuanwu Hospital Capital Medical University approved this retrospective study and written informed consent was obtained from patients before PET/MR examinations.
Table 1

Patient demographics and histopathological characteristics



Total patients


Median age, ranges (y)

54.33, 19–73




22 (66.67%)


11 (33.33%)

Histologic type



4 (12.12%)


2 (6.06%)

  Glioblastoma multiforme

25 (75.76%)


2 (6.06%)

WHO 2016 grade


  Low grade (grade II)

3 (9.09%)

  High grade (grade III–IV)

30 (90.91%)

Newly diagnosed or recurrent


  Newly diagnosed

29 (87.88%)


4 (12.12%)

Tumor-to-brain ratio (TBR)



2.35 ± 0.38


4.91 ± 1.33

Hybrid FET-PET/MR imaging

All PET and MRI examinations were performed simultaneously on a 3-tesla hybrid time-of-flight (TOF) PET/MR (GE Signa, WI, USA) with a 19-channel head-neck coil before biopsy or surgery. A standard MR imaging protocol comprising 3D T2 fluid-attenuated inversion recovery (FLAIR, repetition time/echo time = 9000/maximum), pre- and post-gadolinium 3-dimensional (3D) T1-weighted imaging (T1WI, 8.5/3.2) and axil T1WI, T2WI, FLAIR and diffusion-weighted imaging (DWI) was used. The details of the scan parameters are summarized in Supplementary Table 1.

18F-FET was produced and applied as described previously [24]. All patients fasted for at least 4 h before the examination as recommended, and approximately 200 MBq of 18F-FET was injected intravenously [17]. After a daily routine emission scan for atlas-based attenuation correction with cylinder source [25], FET-PET acquisition started 20 min after tracer injection and required a total acquisition time of 20 min. PET reconstruction was performed with a TOF-point spread function-ordered subset expectation maximization (TOF-PSF-OSEM, 6 iterations and 16 subsets) algorithm on a 128 × 128 matrix, with a 35 cm axial field-of-view and 2.78 mm slice thickness. Emission data were corrected for scattering, random effects, and dead-time coincidences.

Postprocessing and comparison of tumor volumes in different modalities

18F-FET PET and MR imaging data were postprocessed and analyzed in PMOD version 3.505 (PMOD Ltd.). Different modalities were co-registered using nonaffine deformations and manually adjusted by referring to anatomic landmarks. The static PET images were resliced to the same voxel size as 3D T1 CE MRI with 1 × 1 × 1 mm for robust co-registration and more precise volume calculations of glioma [23].

For tumor volume calculations based on CE MRI (VCE) data, we used the 3D auto-contouring segmentation method with an individually determined visual threshold judged by two experienced neuroradiologists in consensus (SS Song and ZG Qi) [14, 26]. The value of the lower threshold was adjusted to identify and separate the contrast-enhanced area from nonenhanced brain tissues. For tumor volume calculations based on FET-PET (VPET) data, the mean background activity was determined using a merged volume of interest consisting of 3 large crescent-shaped regions in the semi-oval center of the unaffected hemisphere, including white and gray matter [27]. VPET was defined by an auto-contouring process with a tumor-to-brain ratio (TBR) threshold of 1.6 or more based on a previous biopsy-controlled study [28]. A manual correction was applied to remove the included blood vessels and other nontumorous tissues with signal intensity or standardized uptake values exceeding the threshold. Necrotic areas and postoperative residual cavities of lesions not showing enhancement or FET uptake were included in the final volume according to surgical criteria [19].

The spatial similarity between VPET and VCE was determined using Dice’s coefficient (DSC) [29]:
$$ \mathrm{DSC}=2\left(\mid {\mathrm{V}}_{\mathrm{PET}}\cap {\mathrm{V}}_{\mathrm{CE}}\mid \right)/\left(\mid {\mathrm{V}}_{\mathrm{PET}}\mid +\mid {\mathrm{V}}_{\mathrm{CE}}\mid \right). $$
We also calculated the overlap volume (OV) [30], which provides the ratio of the intersection to the smallest volume:
$$ \mathrm{OV}=\left(\mid {\mathrm{V}}_{\mathrm{PET}}\cap {\mathrm{V}}_{\mathrm{CE}}\mid \right)/\min\ \left({\mathrm{V}}_{\mathrm{PET}},{\mathrm{V}}_{\mathrm{CE}}\right). $$
To further evaluate the contributions of FET-PET and CE MRI to delineate tumor volume, we calculated the percentages of discrepancy between volumes obtained by FET-PET and CE MRI. Discrepancy-PET (CE) represents the VPET (VCE) that is not included in VCE (VPET) [19]:
$$ \mathrm{Discrepancy}-\mathrm{PET}=\left(\mid {\mathrm{V}}_{\mathrm{PET}}\cup {\mathrm{V}}_{\mathrm{CE}}\mid -{\mathrm{V}}_{\mathrm{CE}}\right)/\left(\mid {\mathrm{V}}_{\mathrm{PET}}\cup {\mathrm{V}}_{\mathrm{CE}}\mid \right)\times 100\%,\mathrm{and} $$
$$ \mathrm{Discrepancy}-\mathrm{CE}=\left(\mid {\mathrm{V}}_{\mathrm{PET}}\cup {\mathrm{V}}_{\mathrm{CE}}\mid -{\mathrm{V}}_{\mathrm{PET}}\right)/\left(\mid {\mathrm{V}}_{\mathrm{PET}}\cup {\mathrm{V}}_{\mathrm{CE}}\mid \right)\times 100\%. $$

Both the DSC and OV values are between 0 and 1. A Dice coefficient value of 1 indicates perfect agreement between VPET and VCE, and an OV value of 1 indicates that one of the volumes, VPET or VCE, completely contains the other. Discrepancy-PET (CE) values range from 0 to 100%. A value of 0 indicates that one of the volumes, VPET or VCE, was completely contained within the other. As the value becomes larger, less of the PET (CE) volume is included in the other.

We next visually assessed the relationship between the abnormal areas on FLAIR and FET-PET images, and divided the 33 patients into 2 types in which VPET was either completely included in (type 1) or partially beyond (type 2) the extent of abnormal signal areas shown on FLAIR.

Stereotactic biopsy procedures

Seven of the patients underwent stereotactic biopsies within a week after PET/MR examinations under the guidance of neuroimaging using co-registered FET-PET and CE MR images loaded into the stereotactic navigation system Robotized Stereotactic Assistant (ROSA, Medtech) [31]. Three to 4 biopsy locations were selected per patient. Biopsy sites were selected only if they were perceived to be safe by both the experienced neurosurgeons (QT Lin and Y Cheng) and neuroradiologists (J Lu and SS Song). Eloquent areas and areas closed to blood vessels were excluded. In all, twenty-four samples were obtained from lesions showing either contrast enhancement and increased FET uptake or increased FET uptake but no enhancement on CE MRI. No postoperative biopsy-related complications were observed. Intraoperative MRI (Siemens, Verio) was used to verify the biopsy site, and 3D Slicer (Version 4.1, SPL, Harvard Medical School) was used to register the preoperative MRI to the intraoperative MRI using the “general registration module.”

All biopsy samples were histologically classified and graded according to the updated 2016 WHO classification of brain tumors [32]. Pathology was determined by two neuropathologists (LM Wang and YS Piao) separately, and discordant results were resolved by consensus. The neuropathologists were blinded to the clinical and imaging data.

Statistical analysis

Statistical analysis was performed using SPSS, version 22 (IBM). Descriptive statistics are shown as the mean and standard deviation or the median and range. The nonparametric Wilcoxon signed-rank test was applied to compare intergroup differences. The Spearman correlation test was performed to calculate the correlation coefficients of VPET and VCE. P values less than 0.05 were considered significant.


Tumor volume analysis

The tumor volume measurements of the 33 patients are shown in Fig. 1a and Supplementary Table 2. The VPET and VCE of all patients were significantly different (P < 0.001, Fig.1b), and the VPET and VCE were positively correlated (r = 0.724, P < 0.001, Fig. 1c). VPET was significantly larger than VCE in 31 patients (93.94%; 77.84 ± 51.74 cm3 on FET-PET vs. 34.59 ± 27.07 cm3 on CE MRI, Z = − 4.860, P < 0.001), while VCE was larger than VPET in only one patient. FET-PET and CE MRI showed similar tumor volumes in one patient (ΔV < 1 cm3).
Fig. 1

aVPET (yellow) and VCE (blue) of the 33 included patients. b There was a significant difference in tumor volumes between FET-PET and CE MRI, which produced average values of 75.75 ± 51.68 and 35.15 ± 28.12 cm3, respectively. c Tumor volume delineated by FET-PET was positively correlated with that delineated by CE MRI (r = 0.724). ***P < 0.001

Overlap and discrepancy between VPET and VCE

The average DSC was 0.56 ± 0.22 (range 0.03–0.86). None of the patients had a DSC greater than 0.9, and only 3 patients (9.09%) had a DSC greater than 0.8. Furthermore, eleven patients (33.33%) had a DSC less than 0.5, indicating low spatial similarity between VPET and VCE (Fig. 2a). In contrast, OV had a larger average of 0.95 ± 0.08 (range 0.65–1.00). Twenty-eight patients (84.85%) had an OV larger than 90% (Fig. 2a and b). In 30 patients (90.91%), VCE was almost contained within VPET, indicated by a discrepancy-CE lower than 10% (mean 1.75 ± 2.23%, range 0–9.23%) (Fig. 2a). None of the patients had a discrepancy-PET less than 10%. However, five patients (15.15%) showed discrepancies between the two modalities of greater than 10% (Fig. 2b). The DSC, OV, discrepancy-PET, and discrepancy-CE metrics of the 33 patients are detailed in Supplementary Table 2.
Fig. 2

A representative comparison of VCE and VPET in patients 11 and 27. a Patient 11: VPET was larger than VCE (37.56 vs. 4.39 cm3). The discrepancy-CE (0.10%) and DSC (0.21) values were low, while the discrepancy-PET (88.33%) and OV values (0.99) were much higher, indicating that almost all of the VCE was contained within VPET. b Patient 27: VPET was larger than VCE (56.00 vs. 38.52 cm3). Both the spatial similarity and overlap were relatively high (DSC 0.53, OV 0.65). However, the discrepancy-PET and discrepancy-CE (44% and 19%, respectively) were both greater than 10%, indicating that FET-PET and CE MRI complemented each other

The relationship between VPET and abnormal areas on FLAIR images

The abnormal signal volumes on FLAIR images were larger than both VCE and VPET. In 22 patients (66.67%), the VPET was completely included within the areas of abnormal signal intensity on FLAIR images (type 1, Fig. 3a). In 11 patients (33.33%), VPET was partly beyond the areas of abnormal signal intensity on T2 FLAIR (type 2, Fig. 3b).
Fig. 3

Representative CE MRI, FET-PET images, and the relationships among the abnormal areas identified on CE MRI, FET-PET, and FLAIR images. a In patient 19, VPET was much larger than VCE. The abnormal signal areas identified on FLAIR image were larger than both VCE and VPET (type 1). b In patient 29, VCE was nearly contained within VPET. VPET was partially beyond the extent of the abnormal signal areas identified on FLAIR image (type 2)

Stereotactic biopsy analysis

A total of 24 samples were obtained from 7 patients by stereotactic biopsy under the guidance of hybrid PET/MR. Thirteen samples were taken from areas with both increased FET uptake and contrast enhancement, 8 samples were obtained from areas with increased FET-PET uptake and no contrast enhancement, and the other 3 samples were obtained from areas negative on both FET-PET and CE MRI but positive on FLAIR images. As expected, all 21 samples obtained from regions of increased FET uptake were pathologically confirmed as glioma tissues or tumor infiltration; however, only 13 of these samples showed contrast enhancement on MRI (Fig. 4). One sample acquired from an area with increased FET uptake but normal signal intensity on FLAIR image was confirmed to contain tumor infiltration by histopathology. Furthermore, three samples were taken from regions with abnormal signal intensity on FLAIR images that were outside of VPET; and 2 of these 3 samples were confirmed to be normal brain tissue, while one contained a small amount of tumor cell infiltration based on histopathology. The PET/MR imaging features and histopathological results of a total of 24 biopsy samples are listed in Supplementary Table 3.
Fig. 4

CE MRI, 18F-FET-PET and FLAIR performed before biopsy, CE MRI performed after biopsy, and hematoxylin and eosin (H&E) staining (×400) of the biopsy samples. a A sample located in the region with increased FET-PET uptake and positive MR enhancement (patient 23). H&E staining showed a cellular glioma corresponding to an astrocytoma of WHO grade II–III with higher local tumor cell density. b A sample located in a region with increased FET-PET uptake and negative MR enhancement. H&E staining showed a cellular glioma corresponding to diffuse astrocytoma of WHO grade II. c A sample located in a region with abnormal signal areas on FLAIR image that did not show increased FET-PET uptake and contrast enhancement. H&E staining showed this area contained normal brain tissue with a small amount of tumor cell infiltration


We found that, in gliomas, a larger proportion of tumor extent was identified by FET-PET than by CE MRI. The histopathology of stereotactic biopsies obtained under the guidance of hybrid FET-PET/MRI confirmed these results. This is the first clinical study to assess tumor volumes simultaneously delineated by FET-PET and MRI using a hybrid PET/MR for gliomas in which the results were validated by stereotactic biopsy. These findings may provide critical information to guide biopsy, surgical, and radiation therapy in patients with gliomas.

During the last few years, interest has increased in the development of applications of 18F-FET PET for tumor grading, differential diagnosis, biopsy guidance, and the assessment of treatment response [11, 17, 20, 33]. The amino acid tracer FET may play a more critical role than FDG in the imaging of gliomas because normal brain tissues show a much lower FET uptake; hence, FET provides clearer borders of lesions. Conventional MRI is the primary clinical reference for image-guided surgery. Therefore, it is meaningful to investigate how the data supplied by FET-PET and conventional MRI are different and whether the application of FET-PET shows superiority in gliomas. We found that the contrast-enhanced regions observed on MRI in gliomas were generally contained within VPET and there was a positive correlation between VPET and VCE. The mechanisms underlying FET uptake and enhancement on MRI are entirely different. FET is transported by specific stereo-selective amino acid transporters, particularly the large neutral amino acid transporter 1 (LAT1). The transportation of FET is not affected by the blood-brain-barrier [21, 34]. Several recent studies have revealed that areas with increased FET uptake correspond to the tumor cell distribution [16, 35, 36]. However, MR contrast accumulates in gliomas due to blood-brain-barrier disruption and is correlated with the histological features of malignant glioma, including cellularity and proliferation [37]. Additionally, the positive correlation between tumor volumes obtained via FET-PET and CE MRI indicates that some underlying pathophysiological factors may exist. Our results indicate that surgical resection guided by CE MRI alone is inadequate for maximizing patient benefits, whereas FET-PET identifies a greater tumor extent, which is critical for planning therapeutic strategies.

The DSC and OV are different parameters used to evaluate the spatial similarity between tumor volumes on FET-PET and CE MRI, with higher DSC values indicating better consistency between VPET and VCE. The OV value represents the ratio of spatial coincidence volume to the smallest tumor volume. In our study, VCE was smaller than VPET in 93.94% of the patients. We found that the spatial similarity between FET-PET and CE was low (average DSC, 0.56), while the OV was high (average, 0.95). These findings illustrate that the spatial biodistribution of gliomas is quite different when manifested using FET-PET versus CE MRI and that basing interpretations on the OV alone may be misleading. Combining DSC and OV could produce a more accurate assessment of the spatial similarity between VPET and VCE. Furthermore, VPET is larger than VCE, and VPET includes most of VCE areas. To validate our findings, we further applied point-to-point stereotactic biopsy studies in 21 regions that showed increased FET uptake with or without MR enhancement. As expected, all samples were confirmed as tumor tissues based on histopathology, but CE MRI identified only 13 (62%) of these regions. Our results support the reliability of FET-PET and the importance of combining both FET-PET and CE MRI to delineate the tumor spatial biodistribution.

To further analyze the differences in glioma spatial biodistribution on FET-PET and CE MRI, we calculated the percentage discrepancy. Two groups of patients with different tendencies were identified. In one group of 30 patients (90.91%), almost all VCE areas were included in VPET, and the discrepancy-CE was less than 10%. However, the other group presented higher discrepancy percentages (> 10%) for both VPET and VCE. These findings are slightly different from those presented in Javier’s study [19],which evaluated the tumor volumes of 23 patients with glioma who preoperatively underwent 11C-MET and MRI. In their study, 9 of 23 patients manifested another pattern in which almost all of the tumor volume observed on MET-PET was contained within the MRI (T1 CE MRI or T2WI)-derived volume. However, seven of these 9 patients were pathologically confirmed to have low-grade II gliomas that were negative on contrast enhancement. We recruited only patients with gliomas that were positive on both FET-PET and CE MRI.

Notably, we visually assessed the relationship between tumor extent on FLAIR and FET-PET images and found that 11 patients (33.33%) showed VPET areas that partly beyond the abnormal signal area on FLAIR images, in agreement with the study by Lohmann et al. [23]. A similar result was also reported by Grosu et al., who found that areas with higher MET uptake were identified beyond the high-signal areas identified on T2W images in 50% of the patients [38]. These findings indicate that even the combination of CE MRI and FLAIR images is inadequate to delineate the full extent of the tumor in glioma patients. In contrast, Pafundi et al. found that all areas showing increased 18F-DOPA uptake were included in the abnormal signal areas on T2W or FLAIR images [12]. In our study, three samples were taken from regions that showed abnormal signal intensity on FLAIR images but were outside VPET. Based on histopathology, two of these 3 samples were confirmed to be normal brain tissue, but one had a small amount of tumor cell infiltration. This result was consistent with those of Arvizu et al. [19]. In addition, several studies have indicated that tumor volumes based on FLAIR or FET-PET imaging findings are predictive of prognosis in glioma [39, 40, 41]. Justin et al. proposed that performing maximum tumor resection according to findings on T2 and FLAIR images was associated with better prognosis in low-grade glioma [41]. Sidsel et al. found that a large tumor volume on FET-PET was an independent predictor of poor survival in GBM patients [42]. The postoperative tumor volume, when based on FET-PET, has also been shown a significant impact on prognosis in GBM patients [39]. FET-PET and FLAIR images show different tumor volumes, and they both play an important role in the evaluating prognosis in glioma; hence, a combination of multimodality imaging to tumor spatial delineation could be valuable for optimal treatment planning.

According to our results, PET/MR is an excellent imaging tool for delineating tumor volumes and identifying glioma boundaries. The integration of PET/MR into the navigation system as well as the development of a preoperative plan are highly recommended. The following limitations should be considered. First, we included a heterogeneous cohort consisting of both newly diagnosed primary and recurrent gliomas in our study. The inclusion of recurrent glioma may have affected the tumor volume assessments because of the effects of previous treatment. However, we did not exclude areas of necrosis or postoperative residual cavities in lesions without enhancement or FET uptake during the tumor volume delineation process according to surgical criteria. Second, no samples were obtained from areas that showed contrast enhancement but no increased FET uptake due to the limited corresponding volumes or their locations (e.g., in eloquence areas or close to blood vessels). Furthermore, a larger cohort of gliomas is needed to confirm the clinical value of multimodality imaging for the management of glioma. Whether FET-PET/MR-guided glioma treatment could improve patient prognosis remains to be investigated in our future work.

In summary, a larger extent of tumor spatial biodistribution was delineated by FET-PET than by CE MRI according to histological confirmation. The spatial similarity between FET-PET and CE MRI was relatively low. Furthermore, our results highlight the importance of combining molecular metabolic imaging (e.g., FET-PET) and anatomic MRI imaging before developing a treatment plan in glioma. Hybrid PET/MR is a promising simultaneous modality that provides opportunities for this application.



The authors thank Hongwei Yang, Yu Yang, Dongmei Shuai, and Lixin Xu for their assistance with the patient studies, and Cheng Peng and Zhigang Liang for the radiosynthesis of FET.


All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Shuangshuang Song, Ye Cheng, Chengyan Dong, Jie Ma, Yukui Wei, Geng Xu, Yang An, Yueshan Piao, Leiming Wang, and Zhigang Qi. The first draft of the manuscript was written by Shuangshuang Song, Ye Cheng, Jie Lu, and Qingtang Lin. all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding information

This work was funded by the Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20180802 to J.L.).

Compliance with ethical standards

The Ethics Committee and Institutional Review Board of Xuanwu Hospital Capital Medical University approved this retrospective study and written informed consent was obtained from patients before PET/MR examinations.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

259_2019_4656_MOESM1_ESM.docx (25 kb)
ESM 1 (DOCX 25 kb)


  1. 1.
    Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.PubMedCrossRefGoogle Scholar
  2. 2.
    Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.PubMedCrossRefGoogle Scholar
  3. 3.
    Herrlinger U, Tzaridis T, Mack F, et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. Lancet. 2019;393(10172):678–88.PubMedCrossRefGoogle Scholar
  4. 4.
    Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma. JAMA. 2017;318(23):2306–16.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Hervey-Jumper SL, Berger MS. Maximizing safe resection of low- and high-grade glioma. J Neuro-Oncol. 2016;130(2):269–82.CrossRefGoogle Scholar
  7. 7.
    Thust SC, Hassanein S, Bisdas S, et al. Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis. Eur Radiol. 2018;28(9):3779–88.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Englander ZK, Horenstein CI, Bowden SG, et al. Extent of BOLD vascular dysregulation is greater in diffuse gliomas without isocitrate dehydrogenase 1 R132H mutation. Radiology. 2018;287(3):965–72.PubMedCrossRefGoogle Scholar
  9. 9.
    Paech D, Windschuh J, Oberhollenzer J, et al. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T. Neuro-Oncology. 2018;20(12):1661–71.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Haider SA, Lim S, Kalkanis SN, et al. The impact of 5-aminolevulinic acid on extent of resection in newly diagnosed high grade gliomas: a systematic review and single institutional experience. J Neuro-Oncol. 2019;141(3):507–15.CrossRefGoogle Scholar
  11. 11.
    Albert NL, Weller M, Suchorska B, et al. Response assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology. 2016;18(9):1199–208.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Pafundi DH, Laack NN, Youland RS, et al. Biopsy validation of F-18-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro-Oncology. 2013;15(8):1058–67.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Pirotte, Benoit JM, Levivier, et al. Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery. 2009;64(3):471–81.PubMedCrossRefGoogle Scholar
  14. 14.
    Filss CP, Galldiks N, Stoffels G, et al. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. J Nucl Med. 2014;55(4):540–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Albert NL, Winkelmann I, Suchorska B, et al. Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans. Eur J Nucl Med Mol Imaging. 2016;43(6):1105–14.PubMedCrossRefGoogle Scholar
  16. 16.
    Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (FET)-F-18-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-Oncology. 2011;13(3):307–16.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Law I, Albert NL, Arbizu J, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2018;46(3):540–57.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Langen K, Watts C. Amino acid PET for brain tumours - ready for the clinic? Nat Rev Neurol. 2016;12(7):375–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Arbizu J, Tejada S, Marti-Climent JM, et al. Quantitative volumetric analysis of gliomas with sequential MRI and 11C-methionine PET assessment: patterns of integration in therapy planning. Eur J Nucl Med Mol Imaging. 2012;39(5):771–81.PubMedCrossRefGoogle Scholar
  20. 20.
    Galldiks N, Langen KJ, Holy R, et al. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. J Nucl Med. 2012;53(7):1048–57.PubMedCrossRefGoogle Scholar
  21. 21.
    Langen K, Stoffels G, Filss C, et al. Imaging of amino acid transport in brain tumours: positron emission tomography with O-(2-[ 18 F]fluoroethyl)- L -tyrosine (FET). Methods. 2017;130:124–34.PubMedCrossRefGoogle Scholar
  22. 22.
    Miwa K. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry. 2004;75(10):1457–62.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Lohmann P, Stavrinou P, Lipke K, et al. FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging. 2019;46(3):591–602.PubMedCrossRefGoogle Scholar
  24. 24.
    Hamacher K, Coenen HH. Efficient routine production of the F-18-labelled amino acid O-(2-[F-18]fluoroethyl)-L-tyrosine. Appl Radiat Isotopes. 2002;57(6):853–6.CrossRefGoogle Scholar
  25. 25.
    Ter Voert EEGW, Veit-Haibach P, et al. Clinical evaluation of TOF versus non-TOF on PET artifacts in simultaneous PET/MR: a dual centre experience. Eur J Nucl Med Mol Imaging. 2017;44(7):1223–33.PubMedCrossRefGoogle Scholar
  26. 26.
    Galldiks N, Ullrich R, Schroeter M, et al. Volumetry of [11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging. 2010;37(1):84–92.PubMedCrossRefGoogle Scholar
  27. 27.
    Munck Af Rosenschold P, Costa J, Engelholm SA, et al. Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma. Neuro-Oncology. 2015;17(5):757–63.PubMedCrossRefGoogle Scholar
  28. 28.
    Pauleit D. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128(3):678–87.PubMedCrossRefGoogle Scholar
  29. 29.
    Henriksen OM, Larsen VA, Muhic A, et al. Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [18F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience. Eur J Nucl Med Mol Imaging. 2016;43(1):103–12.PubMedCrossRefGoogle Scholar
  30. 30.
    Besemer AE, Titz B, Grudzinski JJ, et al. Impact of PET and MRI threshold-based tumor volume segmentation on patient-specific targeted radionuclide therapy dosimetry using CLR1404. Phys Med Biol. 2017;62(15):6008–25.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    De Benedictis A, Trezza A, Carai A, et al. Robot-assisted procedures in pediatric neurosurgery. Neurosurg Focus. 2017;42(5):E7.PubMedCrossRefGoogle Scholar
  32. 32.
    Louis DN, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.PubMedCrossRefGoogle Scholar
  33. 33.
    Galldiks N, Rapp M, Stoffels G, et al. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-l-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging. 2013;40(1):22–33.PubMedCrossRefGoogle Scholar
  34. 34.
    Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-[F-18]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40(1):205–12.PubMedGoogle Scholar
  35. 35.
    Pöpperl G, Kreth FW, Mehrkens JH, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007;34(12):1933–42.PubMedCrossRefGoogle Scholar
  36. 36.
    Jansen N, Graute V, Armbruster L, et al. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging. 2012;39(6):1021–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Ellingson BM, Wen PY, Cloughesy TF. Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. Neuro-Oncology. 2018;20(4):457–71.PubMedCrossRefGoogle Scholar
  38. 38.
    Grosu AL, Weber WA, Riedel E, et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol. 2005;63(1):64–74.CrossRefGoogle Scholar
  39. 39.
    Piroth MD, Holy R, Pinkawa M, et al. Prognostic impact of postoperative, pre-irradiation 18F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol. 2011;99(2):218–24.PubMedCrossRefGoogle Scholar
  40. 40.
    Suchorska B, Jansen NL, Linn J, et al. Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology. 2015;84(7):710–9.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26(8):1338–45.PubMedCrossRefGoogle Scholar
  42. 42.
    Poulsen SH, Urup T, Grunnet K, et al. The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging. 2017;44(3):373–81.PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Authors and Affiliations

  1. 1.Department of RadiologyXuanwu Hospital, Capital medical UniversityBeijingChina
  2. 2.Beijing Key Laboratory of Magnetic Resonance Imaging and Brain InformaticsBeijingChina
  3. 3.Department of Neurosurgery, Xuanwu HospitalCapital Medical UniversityBeijingChina
  4. 4.Department of Nuclear Medicine, Xuanwu HospitalCapital Medical UniversityBeijingChina
  5. 5.Department of Pathology, Xuanwu HospitalCapital Medical UniversityBeijingChina
  6. 6.GE HealthcareBeijingChina

Personalised recommendations